David Waltz is a Respiratory physician affiliated with Vertex Pharmaceuticals. OpenAlex indexes 82 publications with 12,502 citations (h-index 31); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Pediatric Pulmonology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Longwood Ave
Boston, MA 021155724
Telephone
617-355-1900Registry record last updated 11 Sept 2025.
Clinical trials
- A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
2 NIH research awards on record, funded 1994–2006 per NIH RePORTER. The latest:
- A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 28-DAY STUDY OF DEN
Boston Children'S Hospital
FY2006$8,124M01RR002172 - A PHASE 2 RANDOMIZED DOUBLE BLIND PARALLEL DOSE RANGING STUDY OF ORAL THERACLEC-
Children'S Hospital Boston
FY2005$45,754M01RR002172 - 24 WEEKS OF ORAL TREATMENT WITH BIIL 284 BS IN ADULT AND PEDIATRIC CF
Children'S Hospital Boston
FY2005$4,358M01RR002172
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A 192-Week, Phase 3, Open-Label Extension Study
American Journal of Respiratory and Critical Care Medicine
2025 - Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1
Journal of Cystic Fibrosis
2018 - Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis
Journal of Cystic Fibrosis
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Suzan Imren, MD
Vertex Pharmaceuticals
Peter Michelson, MD
Vertex Pharmaceuticals
Laval Chan
Vertex Pharmaceuticals
Tanya Weinstock, MD
Vertex Pharmaceuticals
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Marshall University
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”